|
Professor Michael Cowley is an Australian physiologist. He is best known for his mapping of the neural circuits involved in metabolism and his work obesity and diabetes treatment. He is a Professor in the Department of Physiology at Monash University〔http://www.abc.net.au/rn/lifematters/stories/2009/2726590.htm〕 in the (Faculty of Biomedical and Psychological Sciences ), a Director of an Australian diabetes drug development company, Verva Inc, and Director of the (Monash Obesity & Diabetes Institute ) (modi). Michael is a fellow of The Australian Academy of Technological Sciences and Engineering, a Veski Innovation Fellow and, in 2009, was awarded The Australian Science Minister’s Prize for (Australian Life Scientist of the Year. ) In 2014, Michael was the recipient of the inaugural (Jacques Miller Medal for Experimental BioMedicine ) from the Australian Academy of Science. Michael’s work has mapped the neural circuits in the brain that sense nutrients and fat to control appetite and body weight. He has published more than 75 papers and chapters, is the inventor of 85 patents, and the co-founder of Orexigen Therapeutics, a publicly listed (NASDAQ: OREX) San Diego biotech company, where he served as the Chief Scientific Officer until December 2008, when he returned to Monash University. Michael has a significant focus on public outreach, the promotion of science in schools, and better metabolic health. ==Education== Cowley has a Bachelor of Science from both the University of Melbourne and Monash University. He obtained his PhD at Prince Henry's Institute of Medical Research at Monash Medical Centre, before obtaining a post-doctoral fellowship at The Vollum Institute in Oregon. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Michael Cowley」の詳細全文を読む スポンサード リンク
|